#Canada #financial results #Quebec #Devonian Health Group #Thykamine

Devonian Health Group Reports Financial and Operating Results

Devonian Health Group Inc., a burgeoning name in the biopharmaceutical sector, has publicly shared its financial and operational outcomes for the periods ending April 30, 2026. With a clear focus on therapies for fibro-inflammatory diseases, the company’s latest figures reflect both challenges and progress.

Financial Highlights

During the quarter ended April 30, 2026, Devonian experienced a net loss of $1.9 million, equating to $0.70 per share. This marks an improvement compared to the same quarter last year, which reported a loss of $4.8 million ($1.94 per share). This positive shift is attributed primarily to the absence of a previous year's significant impairment loss related to the company's generic business segment. For the full nine-month review, the total net loss was reported at $5.7 million, or $2.07 per share, up slightly from $5.6 million ($2.28 per share). The incremental loss was largely due to operational expenses, exacerbated by a drop in gross margins following the cessation of sales of a previous product, Dexlansoprazole.

Cash Position and Liquidity

On the liquidity front, Devonian ended April 2026 with cash reserves of $0.7 million, a notable decrease from the $7 million reported at the end of July 2025. During the nine-month period, the company expended $8.4 million in operational activities, balancing some of that loss with cash inflows from private placements amounting to $2 million and warrant exercises totaling $0.2 million. Encouragingly, Devonian remains completely debt-free, providing it with a stable foundation for future investments and developments.

Strategic Focus

Dr. André P. Boulet, CEO of Devonian, expressed enthusiasm about the company’s trajectory as it concentrates on advancing its lead product, Thykamine™. This innovative drug is aimed primarily at preventing radiodermatitis related to radiotherapy and treating Atopic Dermatitis in children. Moreover, the company intends to continue research into the drug's mechanisms of action, laying the groundwork for potentially expanding its use in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) and other fibrotic diseases.

The Future of Thykamine™

Thykamine™—a standout product from the company’s proprietary SUPREX™ platform—exhibits significant promise for addressing conditions tied to inflammation and oxidative stress. Its effectiveness has been confirmed through numerous studies, including a Phase IIa clinical trial for distal ulcerative colitis and robust trials for mild-to-moderate Atopic Dermatitis. With patents secured in various regions, Devonian is well-positioned to innovate within the pharmaceutical landscape.

In Conclusion

As Devonian Health Group charts its path forward, the dual focus on fiscal prudence and scientific exploration stands out. By diligently managing its financial health while pursuing cutting-edge medical solutions, the company not only targets unmet medical needs but also positions itself to make a notable impact in the biopharmaceutical field.

For those keen on learning more about Devonian and viewing its detailed financial reports, further information can be found at Devonian’s Investor Relations Page.